Newsstand Menu

CSHL Stories and Media archive for Tag: leukemia/blood cancers

CSHL scientists identify a new strategy for interfering with a potent cancer-causing gene

2/14/2013

CSHL scientists are identifying and characterizing the molecular mechanisms responsible in order to generate potential new therapeutics. Read the story »

‘Druggable’ protein complex identified as a therapeutic target in acute myeloid leukemia

4/2/2012

Scientists have identified a candidate drug target for treating acute myeloid leukemia (AML). Read the story »

First comprehensive DNA study of mast cell leukemia uncovers clues that could improve therapy

12/16/2011

Sequencing a cancer patient’s “exome” reveals mutations critical for improving diagnostic power and targeted therapy. Read the story »

Cold Spring Harbor Laboratory honors stars of science and sports at sixth annual gala

11/16/2011

Double Helix Medals awarded to Temple Grandin, Harold E. Varmus and Kareem Abdul-Jabbar Read the story »

Unconventional hunt for new cancer targets leads to a powerful drug candidate for leukemia

8/3/2011

Researchers find an unconventional RNAi-based approach to pinpoint a new therapeutic target and drug candidate for acute myeloid leukemia (AML). Read the story »

CSHL scientists reveal mechanism behind ‘oncogene addiction’ in acute leukemia

7/29/2011

Fusion oncoprotein MLL-AF9 ‘hijacks’ Myb to enforce a program of aberrant self-renewal. Read the story »

Cold Spring Harbor Laboratory team shows how loss of key protein promotes aggressive form of leukemia

7/1/2010

p53 loss promotes acute myeloid leukemia (AML) by enabling aberrant self-renewal of myeloid precursors. Read the story »

CSHL study shows that protein linked to leukemia “bookmarks” highly active genes during cell division

1/5/2010

Each cell inherits genes from its parent as well as epigenetic information—what amounts to an instruction manual that specifies which genes Read the story »

CSHL team develops mouse models of leukemia that accurately predict response to chemotherapy

4/1/2009

p53 gene network is key determinant of response; its attenuation causes drug resistance. Read the story »

Collaborative grant propels leukemia research at Cold Spring Harbor Laboratory

10/5/2003

Scott Lowe receives a grant from the Specialized Center of Research to make leukemia treatments less toxic and more effective. Read the story »

Cookie	Duration	Description
cookielawinfo-checkbox-analytics	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checkbox-functional	11 months	The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-necessary	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-others	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-performance	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
viewed_cookie_policy	11 months	The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.